UroGen Pharma (URGN) Tops Q2 EPS by 10c

UroGen Pharma (NASDAQ: URGN) reported Q2 EPS of ($1.17), $0.10 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $13.03 million versus the consensus estimate of $10.21 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
• UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC